Pharmacogenomics and Personalized Medicine

• Autore: Cecchin Erika
• Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
• Descrizione fisica: 1 electronic resource (208 p.)
• Soggetto topico: Medicine
• Soggetto non controllato: CYP2C9; VKORC1; warfarin; warfarin initiation phase of therapy; INR; pharmacogenetics study; pharmacogenomics; pharmacogenetics; genotype; phenotype; alleles; precision medicine; pharmacotranscriptomics; high-throughput analysis; childhood acute lymphoblastic leukemia; clopidogrel; acenocoumarol; CDSS; implementation; azathioprine; inflammatory bowel disease; glutathione-S transferase; pharmacokinetics; nucleoside analogs; microRNAs; gene expression; drug resistance; AML; cisplatin; nephrotoxicity; kidney injury; genetic polymorphisms; pre-emptive; panel; breast cancer subtype; miRNA; pathway; crosstalk network; precision drugs; ovarian cancer; platinum resistance; focal copy number alterations; whole exome sequencing; personalized medicine; human genetics; pharmacology
• Persona (resp. second.): StoccoGabriele; CecchinErika
• Sommario/riassunto: Pharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient’s genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still poor. Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the therapeutic outcome. New investigational approaches are warranted, including a study of the pharmacogenomic role of the immune system genetics and of previously neglected rare genetic variants, reported to account for a large part of inter-individual variability in drug metabolism. In this book, we have collected a series of articles covering many aspects of pharmacogenomics. These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastructures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics.
• Titolo autorizzato: Pharmacogenomics and Personalized Medicine
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910557287703321
• Lo trovi qui: Univ. Federico II